135 related articles for article (PubMed ID: 18006892)
1. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
Vu T; Ellard S; Speers CH; Taylor SC; de Lemos ML; Hu F; Kuik K; Olivotto IA
Ann Oncol; 2008 Mar; 19(3):461-4. PubMed ID: 18006892
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
5. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
[TBL] [Abstract][Full Text] [Related]
7. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
8. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Maniadakis N; Dafni U; Fragoulakis V; Grimani I; Galani E; Fragkoulidi A; Fountzilas G
Ann Oncol; 2009 Feb; 20(2):278-85. PubMed ID: 18842612
[TBL] [Abstract][Full Text] [Related]
10. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
11. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Launois R; Reboul-Marty J; Henry B; Bonneterre J
Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
[TBL] [Abstract][Full Text] [Related]
12. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
14. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Jones SE; Erban J; Overmoyer B; Budd GT; Hutchins L; Lower E; Laufman L; Sundaram S; Urba WJ; Pritchard KI; Mennel R; Richards D; Olsen S; Meyers ML; Ravdin PM
J Clin Oncol; 2005 Aug; 23(24):5542-51. PubMed ID: 16110015
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Melosky B; Peacock S
J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of taxane therapy.
Yee GC
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
[TBL] [Abstract][Full Text] [Related]
20. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
